SREBF1 and prostate carcinoma: Interestingly, the reduction in the synthesis of the enzymes involved in SREBP-1-mediated cholesterol biosynthesis in PC-3 prostate cancer cells suggests that the inhibition of this pathway, due to the Cladosporol–PPARγ complex action, also impedes the de novo intratumoral biosynthesis of androgens.